Takeda Pharmaceutical (NYSE:TAK) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a strong-buy rating to a buy rating in a report published on Saturday morning.

Several other brokerages also recently commented on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $16.61 on Friday. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $17.59 and a two-hundred day moving average price of $16.42. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a market cap of $52.86 billion, a P/E ratio of 42.59 and a beta of -0.06.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 11.23% and a net margin of 4.31%.The firm had revenue of $6.90 billion during the quarter. As a group, analysts anticipate that Takeda Pharmaceutical will post 1.5 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently made changes to their positions in TAK. Arrowstreet Capital Limited Partnership grew its stake in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the period. UBS Group AG lifted its position in Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after acquiring an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp lifted its position in Takeda Pharmaceutical by 98.4% in the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after acquiring an additional 1,143,117 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its position in Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after acquiring an additional 880,289 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.